Pfizer Inc. (PFE)
Pfizer: Oncology Breakthroughs, GLP-1, and Strategic M&A Insights with CFO Dave Denton
In the latest episode of After Earnings, Pfizer CFO Dave Denton shares insights into the company's achievements and future strategies with Ann Berry and Katie Perry. They discuss topics like acquiring Seagen, the use of AI in drug development, and ongoing initiatives in oncology and weight management. Denton addresses shareholder concerns about financial performance, emphasizing Pfizer's dedication to innovation through significant investments in M&A and R&D. He also highlights the development of an oral GLP-1 receptor for obesity management and efforts to maintain robust dividends.
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.
Pfizer: Undervalued Healthcare Leader Poised For Further Recovery
Pfizer's transition from COVID revenue faces skepticism, as PFE underperformed its healthcare peers recently. Successful integration of Seagen is crucial for Pfizer's oncology portfolio, potentially lifting investor sentiment. Pfizer's cautious approach to weight loss drugs suggests success is far from certain, raising its execution risks to disrupt the market.
Pfizer Is Rising Past Covid-19
Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high.
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever
Now that W.P. Carey is no longer in the office-leasing business, its long-term investors can rest much easier.
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
The healthcare giant was a star stock during the height of the pandemic thanks to its vaccine. Some Pfizer investors are hungry for an encore and showing their displeasure by shunning the stock.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pfizer's 5.7% dividend yield stands out in the healthcare sector. The company's 436% payout ratio raises concerns about dividend sustainability.
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the condition, called cancer cachexia, who took Pfizer's treatment saw improvements in body weight, muscle mass, quality of life and physical function.
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the standard of care.
